Loading stock data…
WAT
$334.93-17.28 (-4.91%)
Pre-Market$334.71-0.22 (-0.07%)· Last close May 13
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Waters Corporation in the Healthcare sector is trading at $334.93. Wall Street consensus targets $398.38 (21 analysts), implying a +18.9% move over the next 12 months. The stock is currently 19% below its 52-week high of $414.15, remaining 0.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +18.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$334.93
Potential Downside
18%
Whystock Fair Value$274.61
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Buy
Mean target$398.38+18.9%
Range$345.00 – $480.00
Fundamentals
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spect...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$32.82B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
31.05
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
25.82%
Volume
Today's trading volume
1.23M
Recent News
Waters Merger With BD Recasts Growth Profile And Integration Test For Investors
Waters Corporation (NYSE:WAT) has completed a merger with BD’s Biosciences and Diagnostic Solutions businesses. The transaction is described as transformative for Waters, more than doubling its revenue base. Management is targeting operational synergies and pointing to strong early execution and demand in pharmaceutical markets. The combined company is placing greater focus on biologics, along with government and academic customers. Waters is best known for its analytical instruments and...
Is Waters Corporation (WAT) A Good Stock To Buy Now?
Is WAT a good stock to buy? We came across a bullish thesis on Waters Corporation on The Wealth Dynasty Report’s Substack. In this article, we will summarize the bulls’ thesis on WAT. Waters Corporation’s share was trading at $301.88 as of May 4th. WAT’s trailing and forward P/E were 28.54 and 21.37 respectively according to Yahoo […]
What Makes Waters Corporation (WAT) an Investment Bet?
Artisan Partners, an investment management company, released its first-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. A copy of the letter is available to download here. In Q1 2026, the Artisan Mid Cap Fund reported negative absolute returns but slightly outperformed the Russell Midcap® Growth Index. The market favored lower volatility and income-oriented equities, […]
Jim Cramer Highlights Acquisition By Waters Corporation Following Quarterly Results
Waters Corporation (NYSE:WAT) was one of the stocks on Jim Cramer’s radar as he highlighted AI winners to buy for 2026. Cramer explained why the stock rallied, as he said: Can you believe these incredible numbers from Waters Corporation? This is the arms dealer to the life science industry. Recently acquired Becton, Dickinson’s Biosciences and […]
WAT Q1 Earnings Beat Estimates, BD Acquisition Aids Revenues
Waters crushes Q1 2026 estimates as revenues surge 91.5%; newly acquired BD units top targets early, and 2026 guidance moves higher.